Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifabutin

FDA-approved product (capsule, oral), marketed as Mycobutin, Rifabutin.

Registered studies
50+
Lab records
15
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rifabutin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Mycobacterium avium complex disease
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
FDA pharmacologic class
Rifamycin Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB04; FDA class Rifamycin Antimycobacterial

Repurposing investigation

Rifabutin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA84.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli64.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 15 of 15 lab records
Open Rifabutin in ChEMBL Registered studies below
Show the 15 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifabutin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

    NCT00002080

    Registered record
    Registry ID
    NCT00002080
    Conditions
    Mycobacterium Avium-intracellulare Infection; HIV Infections
    Interventions
    Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-intracellulare Infection; HIV Infections
    InterventionRifabutin
    PhaseNot applicable
    Registry statusCompleted

  • A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo

    NCT00002101

    Registered record
    Registry ID
    NCT00002101
    Conditions
    Mycobacterium Avium-Intracellulare Infection; HIV Infections
    Interventions
    Ethambutol hydrochloride; Clarithromycin; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-Intracellulare Infection; HIV Infections
    InterventionEthambutol hydrochloride; Clarithromycin; Rifabutin
    PhasePhase 3
    Registry statusCompleted

  • Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

    NCT00002267

    Registered record
    Registry ID
    NCT00002267
    Conditions
    Mycobacterium Avium-intracellulare Infection; HIV Infections
    Interventions
    Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-intracellulare Infection; HIV Infections
    InterventionRifabutin
    PhaseNot applicable
    Registry statusCompleted

  • A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS

    NCT00002343

    Registered record
    Registry ID
    NCT00002343
    Conditions
    Mycobacterium Avium-Intracellulare Infection; HIV Infections
    Interventions
    Ethambutol hydrochloride; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-Intracellulare Infection; HIV Infections
    InterventionEthambutol hydrochloride; Rifabutin
    PhasePhase 4
    Registry statusCompleted

  • Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

    NCT00004736

    Registered record
    Registry ID
    NCT00004736
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Nelfinavir mesylate; Ethambutol hydrochloride; Isoniazid; Pyrazinamide; Lamivudine; Rifabutin; Stavudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionNelfinavir mesylate; Ethambutol hydrochloride; Isoniazid; Pyrazinamide +4 more
    PhasePhase 1
    Registry statusCompleted